Treatment of chronic hepatitis C with interferon alfa‐n3: A multicenter, randomized, open‐label trial
D M Simon, S C Gordon, M M Kaplan, R S Koff, F Regenstein, G Everson, Y M Lee, F Weiner, A Silverman, T Plasse, D Fedorczyk, M Liao – 30 December 2003 – We studied the antiviral effectiveness and safety of interferon alfa‐n3, a natural alpha interferon which contains multiple interferon species, in the treatment of previously untreated patients with chronic hepatitis C. Seventy‐seven patients were randomized to receive either 1.0, 2.5, 5.0, or 10.0 million units (MU) of interferon alfa‐n3 three times a week for 24 weeks and were then followed for an additional 24 weeks.